{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:09:38Z","timestamp":1793686178902,"version":"4.5.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"JSC R-Pharm"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1136\/ard-2022-222630","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T13:21:14Z","timestamp":1663248074000},"page":"1661-1668","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study"],"prefix":"10.1016","volume":"81","clinical-trial-number":[{"clinical-trial-number":"nct02760433","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02760433","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01604343","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02015520","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03744910","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Eugen","family":"Feist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3005-9439","authenticated-orcid":false,"given":"Saeed","family":"Fatenejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Grishin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4085-5869","authenticated-orcid":false,"given":"Elena","family":"Korneva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E","family":"Luggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1598-8360","authenticated-orcid":false,"given":"Evgeniy","family":"Nasonov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Samsonov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6630-1477","authenticated-orcid":false,"given":"Roy M","family":"Fleischmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2022-222630_bib1","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-222630_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222630_bib3","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222630_bib4","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"10.1136\/ard-2022-222630_bib5","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1007\/s10067-019-04684-1","article-title":"Defining response to TNF-inhibitors in rheumatoid arthritis: the negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders","volume":"38","author":"Johnson","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2022-222630_bib6","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222630_bib7","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"Il-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1136\/ard-2022-222630_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000887","article-title":"Long-Term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment","volume":"5","author":"Genovese","year":"2019","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-222630_bib9","first-page":"143","article-title":"Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis","volume":"6","author":"Hushaw","year":"2010","journal-title":"Ther Clin Risk Manag"},{"key":"10.1136\/ard-2022-222630_bib10","author":"Kenney"},{"key":"10.1136\/ard-2022-222630_bib11","doi-asserted-by":"crossref","first-page":"774","DOI":"10.4161\/mabs.28612","article-title":"Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling","volume":"6","author":"Shaw","year":"2014","journal-title":"MAbs"},{"key":"10.1136\/ard-2022-222630_bib12","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1136\/annrheumdis-2013-204760","article-title":"Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised phase IIb study","volume":"73","author":"Genovese","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222630_bib13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/14397595.2015.1074648","article-title":"Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: results from a randomized phase II trial","volume":"26","author":"Takeuchi","year":"2016","journal-title":"Mod Rheumatol"},{"key":"10.1136\/ard-2022-222630_bib14","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1056\/NEJMoa2201302","article-title":"Olokizumab versus placebo or adalimumab in rheumatoid arthritis","volume":"387","author":"Smolen","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-222630_bib15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/annrheumdis-2021-219876","article-title":"Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study","volume":"81","author":"Nasonov","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222630_bib16","series-title":"Multiple imputation for nonresponse in surveys","author":"Rubin","year":"1987"},{"key":"10.1136\/ard-2022-222630_bib17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/art.39944","article-title":"Sarilumab and Nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222630_bib18","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222630_bib19","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/ard.2007.071415","article-title":"Treatment-Related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results","volume":"67","author":"Aletaha","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222630_bib20","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1136\/ard.2009.114652","article-title":"Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222630_bib21","article-title":"P131 Efficacy and safety of olokizumab in a phase III trial of patients with moderately to severely active RA inadequately controlled by methotrexate: placebo and active controlled study","volume":"60","author":"Feist","year":"2021","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-222630_bib22","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"Il-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1136\/ard-2022-222630_bib23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/09629359890875","article-title":"Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis","volume":"7","author":"Robak","year":"1998","journal-title":"Mediators Inflamm"},{"key":"10.1136\/ard-2022-222630_bib24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.smim.2013.11.002","article-title":"Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities","volume":"26","author":"Scheller","year":"2014","journal-title":"Semin Immunol"},{"key":"10.1136\/ard-2022-222630_bib25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study","volume":"76","author":"Dougados","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222630_bib26","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222630_bib27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/annrheumdis-2021-eular.1532","article-title":"OP0127\u2005CONFOUNDING EFFECTS OF CONTINUED METHOTREXATE IN PLACEBO ARMS (PLC) OF RHEUMATOID ARTHRITIS (RA) CLINICAL TRIALS \u2013 A POST-HOC ANALYSIS OF TWO RANDOMIZED CONTROLLED TRIALS (RCTS)","volume":"80","author":"Kerschbaumer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222630_bib28","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/annrheumdis-2021-221807","article-title":"Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis","volume":"81","author":"Kerschbaumer","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222630_bib29","article-title":"Efficacy and safety of Olokizumab in a phase III trial of patients with moderately to severely active rheumatoid arthritis inadequately controlled by TNF-\u03b1 inhibitor therapy","volume":"73","author":"Fleischmann","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222630_bib30","article-title":"P136\u2003Efficacy and safety of olokizumab in a phase III trial in patients with moderately to severely active RA inadequately controlled by TNF-\u03b1 inhibitor therapy","volume":"60","author":"Feist","year":"2021","journal-title":"Rheumatology"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724087326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724087326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2022-222630","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T03:36:36Z","timestamp":1739504196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724087326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0003496724087326"],"URL":"https:\/\/doi.org\/10.1136\/ard-2022-222630","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2022-222630","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 \u00a9 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}